Quarterly report pursuant to Section 13 or 15(d)

Revenue and Accounts Receivable - Additional Information (Detail)

v3.5.0.2
Revenue and Accounts Receivable - Additional Information (Detail)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
USD ($)
company
Jun. 30, 2015
USD ($)
company
Jun. 30, 2016
USD ($)
company
Jun. 30, 2015
USD ($)
company
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue $ 7,001 $ 4,185 $ 13,069 $ 8,555
Number of companies that accounted for approximately 10% or more of revenue | company 2 1 2 2
Payor | Testing Volume | Clinical Testing        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Percentage of benchmark 40.00% 61.00% 38.00% 66.00%
Payor | Testing Volume | Community Hospitals        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Percentage of benchmark 6.00% 22.00% 7.00% 23.00%
Payor | Sales | Customer One | 10% or More Clinical Revenue        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Percentage of benchmark 15.00% 25.00% 13.00% 26.00%
Payor | Sales | Customer Two | 10% or More Clinical Revenue        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Percentage of benchmark 11.00%   11.00% 14.00%
Clinical Services        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue $ 2,542 $ 1,251 $ 4,998 $ 2,124
Clinical Services | Response Genetics, Inc.        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue $ 1,425   $ 3,129